Chronic leukaemia by Xuereb, J. & Blundell, Renald
Research Journal of Medical Science 2 (1): 28-32, 2008
ISSN: 1815-9346
© Medwell Journals, 2008
Corresponding Author: R. Blundell, Department of Physiology and Biochemistry, Biomedical Science Building, 
Faculty of Medicine and Surgery, University of Malta, Msida MSD06, Malta
28
Chronic Leukaemia
J. Xuereb and R. Blundell
Department of Physiology and Biochemistry, University of Malta, Msida MSD06, Malta
Abstract: Chronic leukaemia manifests itself into two different types being Chronic Lymphocytic Leukaemia
(CLL)  and  Chronic  Myelogenous  Leukaemia  (AML)  depending  on the type of leukocyte being affected.
CLL is the most common type of leukaemia in adults in contrast to CML which is the rarest type of leukaemia.
This study shows the epidemiology and the etiology, such as chromosomal aberrations and gene mutations
which include upregulation of Bcl2, mutation of p53, 13q deletion, 11q22-23 deletion, 12q trisomy and 17p
deletion for CLL and the fusion of the BCR and ABL genes in CML. It also includes the clinical presentations
consisting of both signs and symptoms as well as how these types of leukaemia are diagnosed and their
pathophysiology which comprises a detailed description of the alterations in various cellular mechanisms. The
treatment involving both chemotherapy and stem cell therapy, amongst others, has also been discussed.
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INTRODUCTION reclassified by the World Health Organisation as T-Cell
Leukaemia is ‘a  progressive, malignant disease of the It is the only leukaemia not associated with exposure
blood-forming organs, characterised by distorted prolife- to ionising radiation, drugs or chemicals. But it was
ration and development of leukocytes and their precur- observed that the incidence of CLL in the relatives of the
sors in the blood and bone marrow’. CLL patients  is  higher  suggesting  that  CLL occurs in
There  are  two  common  types  of  chronic 5-10% of patients (Yee and O’Brien, 2006).
leukaemia  being the Chronic Lymphocytic Leukaemia CLL  patients presented night sweats, weight loss
(Chronic lymphoblastic leukaemia) and the Chronic and fatigue as well as lymphadenopathy, splenomegaly
Myelogenous Leukaemia. and hepatomegaly. The peripheral blood lymphocyte
The term chronic implies that the disease progresses count  was  found to be more than 5×10  LG . the typical
slowly and the growth of relatively larger number of B-cell ALL immunophenotype is CD5+, CD19+, CD23+,
developed cells is permitted. Such cells can carry out FMC7-, negative expression of CD22, CD79b and surface
some of the functions but this condition worsens membrane immunoglobulin (Yee and O’Brien, 2006).
progressively. During the process of normal B-cell maturation.
The types of leukaemia are also categorised Somatic hypermutation of the variable region of the Ig
according to the type of leukocyte being affected. In heavy chain gene (IgVh) in the lymphatic follicle is an
lymphocytic leukaemia, malignant lymphoid cells are important station. (Méhes, 2005). The presence of
observed while abnormalities in myeloid cells are found in unmutated IgVh genes in CLL is considered to be an
myelogenous leukaemia. adverse prognostic factor (Yee and O’Brien, 2006).
CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) IgvH gene arises and this occurs via the presence of the
CLL is the most common leukaemia of adults in
Western  Countries  (Schriever and Huhn, 2003). It PATHOPHYSIOLOGY
accounts  for  25% of all leukaemia cases and affects
about  3 in every 100,000 persons in the United States Inhibition of the programmed cell death (apoptosis)
(Yee and O’Brien, 2006). It originates from B-cells (B-CLL) and upregulation of the anti-apoptopic protein Bcl-2.
in 95%  of leukaemia cases and only a minority of patients Mutations of p53 were also observed in some CLL cases
are affected by leukaemia originating from T-Cells (T-CLL) which result in poor clinical response to therapy with
(Schriever and Huhn, 2003). The T-Cell CLL has been alkylating agents such as chlorambucil. 
Prolymphocytic Leukaemia (PLL) (Yee and O’ Brien, 2006).
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Therefore, the need to analyse the mutation state of the
CD38 and ZAP70 biomarkers (Méhes, 2005).
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Genetic aberrations were also detected in 50-80% of Fludarabine is a purine-analogue and it inhibits DNA
CLL case (Méhes, 2005) and were listed according to their
decreasing frequency being:
C 13q deletion (55%)
C 11q deletion (18%)
C 12q trisomy (16%)
C 17p  deletion  (7%)  (Méhes,  2005; Schriever and
Huhn, 2003)
13q deletion: The deletion can be either pinpointed on a
single locus (q14) or can be accompanied with a loss of
larger interstitial region of the long arm of the
chromosome. Two hypothesis are involved in the
manifestation of this deletion. The first one is about an
unidentified tumour suppressor gene being included in
the deletion. On the contrary, the second hypothesis
states that the deleted 13q 14.3 region would include
genes coding for micro RNA (miRNA) which are capable
to regulate cellular activation by interacting with the
genomic DNA. Therefore, this will impair disease
progression (Méhes, 2005).
11q22-23 deletion: The ATM (Ataxia Telangiectasia)
gene is included in this deletion. This gene is involved in
the cellular apoptopic pathway through the activation of
p53. The ATM gene loss results in reduced cell-death
(Méhes, 2005). 
12q trisomy: This trisomy has been linked to activated
genes present at 12q which may be involved in disease
progression. (Méhes, 2005).
17p deletion: This deletion is associated with the loss of
certain genes which are important in cell cycle regulation
since they are found at the 17p13 locus. One of such
genes is the p53 tumor suppressor gene and as a result
CLL cells may survive and accumulate further genetic
defects (Méhes, 2005).
Apart from the previously mention chromosomal
aberrations, further studies have shown that the level of
activation of the human Telomerase Reverse
Transcriptase (hTERT) gene  was  found  to increase in B-
CLL. hTERT is  the  gene  which  codes  for  the  catalytic
subunit of the  telomerase  enzyme.  This  was to blame for
the clinical aggressiveness and poor prognosis in CLL
(Tchirkov et al., 2004).
TREATMENT
Chlorambucil is a bifunctional alklylating drug and is
the standard treatment against CLL. It presents remission
rates up to 40% with only 3% complete remission with the
latter having a short duration.
synthesis by interfering with ribonucleotide reductase
and DNA polymerase. It is active against both dividing
and resting cells. It is the most active single agent in CLL
treatment and is indicated for B-CLL patients. However, it
is also used as a first line of treatment with 80% remission
rates and up to 60% complete remission rates. If given to
relapsed patients after treatment with this drug, remission
rates increase to 83%. The adverse effects connected to
Fludarabine  are  myelosuppression,  lymphocytopenia
and  specific damage of CD4+ T cells (Schriever and
Huhn, 2003).
Another purine analogue involved in CLL treatment
is Cladribine having an efficacy similar to fludarabine. It
presents complete remission rates of 67%. The adverse
effects are similar to fludarabine.
Rituximab is a chimeric monoclonal antibody that
binds  to  the  surface  antigen  CD20  which  expression
is  restricted  to  B-cell  malignancies  (Schriever and
Huhn, 2003). 
Alemtuzumab is another chimeric monoclonal
antibody which binds to the CD52 antigen. CD52 is
strongly expressed on malignant B-cells including CLL
cells and lymphoblastic leukemia cells. The drug promotes
transmembrane signaling and induces apoptosis through
a caspase-3-dependent pathway. Infections are its major
adverse effects (Schriever and Huhn, 2003).
High dose therapy followed by autologous stem cell
transplantation ie transplantation of stem cell obtained
from host. This always leads to reinfusion of
contaminating leukemic cells. Stem cell purging must be
performed by B cell negative selection, CD34+ B-cell
selection or combination of both methods. Ineffective
purging leads to relapse. Transplant related mortality
varies  between 4 and 19%. Approximately 80% of
patients achieve complete remission and 40-50% are alive
after 4 years. But in most studies, 50% of patients have
relapsed at 4 years.
High  dose chemotherapy followed by allogeneic
stem  cell  transplantation  that  is  stem cells obtained
from a donor. Higher mortality rates have been observed
that varied between 25 and 50% of all patients with
relapse rates escalating between 10-25% of patients
(Schriever and Huhn, 2003).
CHRONIC MYELOGENOUS LEUKAEMIA
Chronic myelogenous leukaemia is a rare disease
represents 14% of all leukaemias and 20% of adult
leukaemias worldwide. The incidence is 1.6 cases per
100,000  adults per year and the male to female ratio is
1.4:1  in  the  Unites  States  (Cardama  et  al.,   2006).
CML incidence increases exponentially with age. It was
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statistically  proven that the median age at diagnosis is blast and promyelocyte count in marrow or peripheral
65-67  years  (Cardama  and Cortes, 2006; Lee, 2000) On blood samples. Several definitions are still being studied
the other  hand,   CML   is exceedingly rare in children for the accelerated phase and blast crisis as there are still
(Lee, 2000). some discrepancies in the blood count values obtained
The disease is not preventable and neither inherited (Cardama and Cortes, 2006). 
since there is no known hereditary, familial, geographic,
ethnic, or economic association with CML. It can be PATHOPHYSIOLOGY
concluded, that neither chemical exposure nor genetic
predisposition is thought to induce CML (Cardama and The fusion of the ABL1 and BCR genes results in the
Cortes, 2006). Ionizing radiation in high doses is the only activation of the c-ABL protooncogene to its oncogenic
known risk factor (Lee, 2000). CML can also be due to a active form. The breakpoints at the 9q34 within the ABL1
reciprocal chromosomal translocation which involves the gene represent an area spanning more than 300 kilobase
ABL1 proto-oncogene on chromosome 9 and the BCR pairs (upstream of exon b1 and downstream of exon 1a).
gene (i.e. the breakpoint cluster region) on chromosome On the other hand, breakpoints within the BCR gene are
22 to form the Philadelphia chromosome (Cardama and restricted to 3 main breakpoint cluster regions. 
Cortes, 2006). In most patients with CML, the break occurs within
CLINICAL PRESENTATION AND DIAGNOSIS b1-b5). This is referred to as the M-bcr-major breakpoint
CML is described in 3 phases of disease progression. transcript  with  either  b2a2  or  b3a2  junctions  can
These are: result  and will give rise to a 210-kd hybrid protein
C Chronic Phase (CP) Figure 1 depicts the location of the M-BCR in the
C Accelerated Phase (AP) BCR gene on chromosome 12 and the location of
C Blast Phase (BP) (Cardama and Cortes, 2006) breakpoints within the ABL gene on chromosome 9. 
Patients suffering from chronic phase CML account important functional domains which are shown in Fig. 2.
to 90% of all CML patients. They have effective immune
systems and generally feel well for a relatively long period
of time. When symptoms and signs are present, they are
usually mild and related to expansion of the CML cells.
Thus the common symptoms include fatigue, weight loss,
bone ache and splenomegaly. This phase is usually
described as a benign premalignant state, as the disease Fig. 1: Locations of the breakpoints in the BCR and
is  easily managed with outpatient therapy during the ABL genes (Inokuchi, 2006)
early stage. Still after 3 to 8 years it becomes an acute
leukaemia that is rapidly fatal. The progression of the
disease after 2 years of diagnosis results in 5-10 patients
developing blast crisis. The progression rate then
increases by 20-25% per year (Lee, 2000). 
When CML enters an advanced stage, patients
present also an inability to control leukocyte counts with Fig. 2: The functional domains on the p210 BRR/ABL
previously stable doses of medication, fevers, night include the oligomerisation domain (coiled-coil
sweats and splenic infarcts from excessive splenomegaly. motif), the tyrosine 177 (Grb-2 binding site), the
The platelet count may either be high or low. There is also phosphoserine/threonine-rich SH2-binding
an increase in basophil, eosinophil, promyelocyte and domain and the rho-GEF (DBL-like) domain on
blast count. This hastened phase suggests a more the BCR portion and the regulatory src
aggressive cytogenetic abnormality apart from the homology regions SH3 and SH2, the SH1
Philadelphia chromosome. Additional abnormalities (tyrosine kinase domain), the Nuclear
include trisomy 8, trisomy 19, a duplicate Philadelphia Localization Signal (NLS) and the DNA- and
chromosome and isochromosome. The blast crisis actin-binding domains in the ABL portion
mentioned previously is characterized by having a 20-30% (Inokuchi, 2006)
a  5.8-kb  area  spanning  the BCR exons e12-e16 (or the
cluster region. Due to alternative splicing, a fusion
(p210BCR-ABL). 
The p210BCR-ABL protein possesses various
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Fig. 3: The activation of signal transduction pathways
by BCR/ABL (Cardama and Cortes, 2006) Using interferon: The use of recombinant human
Several pathways are activated in p210BCR-ABL immunomodulatory activity in the treatment of CML.
expressing cells. Phosphorylation at the Y177 site of BCR Several results have been reported such as Major
is very important in p210BCR-ABL leukemogenesis. This Cytogenetic Responses (MCGRs) (<35% Ph chromosome-
residue  makes  up  a  high-affinity docking site for the positive cells) in up to 40% of patients and Complete
SH2  domain  of  Grb2  (growth  factor  receptor-bound Cytogenetic Responses (CCGRs) (0% Ph chromosome-
protein 2). Subsequently, Grb2 engages SOS  (a  guanine- positive cells) in up to 25% of the population studied.
nucleotide  exchanger  of  RAS)  and a scaffold adapter When cytarabine was used in combination with this
Grb2-Associated  Binding  protein  2  (GAB2)   through therapy this resulted in a significant higher probability of
its  SH3 domain. GAB2 is phosphorylated and this  leads a CCGR in about 35% of the patients. This proves the fact
 to  the  recruitment   of   Phosphatidylinositol  3-Kinase of increased survival rates thus proving the use of CCGR
(PI3K) and SHP2 (also known as PTPN11). The SOS the interferon alfa therapy (Cardama and Cortes, 2006). 
activates RAS (Cardama and Cortes, 2006). 
Grb2 binding and the Bcr-Abl induced RAS Stem Cell Transplantation (SCT): This is still and
activation are interrupted due to a mutation of Y177 to remains an important treatment option. SCT performed
phenylalanine (Y177F). The Y177F mutation ceases the within 12, 24 months and within first 36 months, from the
transformation of primary bone marrow cultures. The diagnosis have been suggested to possibly have similar
BCR-ABL complex also phosphorylates Src kinases i.e. outcomes. Recently it was discovered that interferon alfa
Lyn, Hck and  Fgr.  Following  phosphorylation,  the  Hck therapy had no adverse effect and that exposure to
activates STAT5 (Signal Transducer and Activator). imatinib does not affect the outcome either. A strategy
Disease progression has been correlated with over was recently proposed to overcome the lack of compatible
expression of the previously mentioned Hck/Lyn donors-this is the use of Matched Unrelated Donors
(Cardama and Cortes, 2006). (MUDs). Still this is still being studied. The result of MUD
It was concluded that BCR-ABL promotes the SCT may be improved by careful molecular typing,
haematopoietic cell transformation. This occurs mainly especially for HLA-A, HLA-B and HLA-DRB1. Still, the
through the RAS, PI3K and STAT 5 activation. All these use of stringent typing criteria is closely linked to a lower
steps cause upregulation of the expression of cyclins probability of finding a compatible donor. Additional
especially cyclin D1 which causes the cell to progress disadvantages and risks associated with SCT include
from the G1 to the S phase. When BCR-ABL1-positive graft-vs-host disease, veno-occlusive disease, life-
K562 cells were induced to express the dominant negative threatening infections, risk of secondary malignancy,
forms of RAS, PI3K, or STAT 5, apoptosis was observed decreased overall quality of life and the risk of late
(Cardama and Cortes, 2006). relapse. The long-term survival rate after MUD-SCT for
Studies proved that Bcr-Abl also enhances SET young  patients  in  the  early CP stage of disease is 57%
expression (nucleus/cytoplasm-localized phosphoprotein when  compared  with  67%  in patients who receive grafts
that potently inhibits the tumor suppressor protein
phosphatase 2A-PP2A). This occurs mainly during
progression to the Blast Phase. PP2A regulates cell
proliferation, survival and differentiation (Cardama and
Cortes, 2006). Figure 3 illustrates the main signal
transduction pathways activated by BCR/ABL.
TREATMENT
Tyrosine kinase inhibitors are essential in treating
CML.  Until  a few years ago, interferon alfa and SCT
(Stem Cell Transplantation) were the only therapeutic
options. Currently, SCT is still being used as an option
especially for patients who do not respond appropriately
to Tyrosine Kinase Inhibitors (TKIs). However, the use of
molecularly targeted TKIs in recent years led by imatinib
mesylate has brought a change in the treatment of CML
(Cardama and Cortes, 2006). 
interferon alfa has shown relative antitumor and
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from HLA-matched siblings. The long-term survival in competitive, dual-specific Src- and Abl-kinase inhibitor
patients has been improved by recent molecular matching
incorporation. This has decreased the rate of graft-vs-
host disease. Reduced-intensity conditioning regimens
have been used to make SCT available to an increased
number  of  patients  who otherwise  would  be  ineligible
for standard SCT. This makes use of the T cells found in
the graft to eliminate the CML cells (graft-vs-leukaemia
effect). This increases tolerability and decreases morbidity
and mortality of the patient (Cardama and Cortes, 2006). 
Imatinib mesylate: Imatinib mesylate (Gleevec) can be
described as an orally bioavailable 2-phenylamino-
pyrimidine with targeted inhibitory activity against the
active tyrosine kinase of the Bcr-Abl chimeric fusion
protein.  Imatinib  also  inhibits  other  kinases,  such  as
c-Kit,  platelet-derived  growth  factor  "  and   $   and
Abl-Related Gene (ARG). Nowadays Imatinib has become
the standard therapy for CML because is it has an
effective and efficient  activity  and mild toxicity profile.
Imatinib therapy was found to have an increased effect
when compared to interferon alfa plus low dose
cytarabine (when taking into account the hematologic,
cytogenetic responses, tolerability and transformation to
CML-AP). The  results  from  the  International
Randomized Study of  Interferon  and  STI571   have 
established  imatinib 400 mg dG , as the standard therapy1
for CML. Still a disadvantage with Imatinib therapy is that
most patients who have discontinued it experience a
molecular and cytogenic relapse. Some patients with CML
also exhibit either primary or secondary resistance to
imatinib (Cardama and Cortes, 2006). 
Treatment strategies being developed for the future Bcr-
abl  inhibitors:  This  is one of the strategies currently
being developed to overcome imatinib resistance. New
Abl TKIs have been developed with an increased potency
and less stringent binding requirements and also with
inhibitory activity against other kinases. New agents that
block Bcr-Abl in a non-ATP competitive manner are being
proposed as an alternative for patients who develop
imatinib-insensitive Bcr-Abl kinase mutations.
Nilotinib (AMN107): This is a phenylamino-pyrimidine
derivative with a 20-30 fold increased potency when
compared with imatinib against Bcr-Abl. 
Dasatinib  (BMS-354825):  It   was  found  that  inhibition
of    Bcr-Abl   alone  may  not  be  sufficient  to  destroy
 all of  the  CML  cells,  particularly  the  leukemic  imatinib
 in sensitive quiescent  stem  cells.  Dasatinib  is  an  ATP
with a 100-300 fold higher potency against Bcr-Abl
compared with imatinib. 
Non-ATP-competitive Bcr-Abl inhibitors: Imatinib,
nilotinib and dasatinib are ATP-competitive inhibitors.
Therefore, these molecules can be affected by the T315I
mutation, which was described as the gatekeeper of the
kinase domain. Due to this, non-ATP- competitive
compounds are also being used. They compete with
natural  substrates  such  as  Crkl   but   not   with   ATP
(in the case of ON012380) (Cardama and Cortes, 2006).
Additional therapy include:
C Farnesyl transferase inhibitors (such as lonafarnib -
these have demonstrated activity both as single a
agent and in combination with imatinib. 
C Homoharringtonine - A Cephalotaxus alkaloid which
is found to be the best therapeutic option in patients
in whom interferon alfa–based therapies failed.
C Hypomethylating agents and histone deacetylase
inhibitors.
Use of vaccines to elicit specific immune responses
directed toward CML-restricted tumor antigens since
immune-mediated events play an important role in the
suppression of the CML clone (Cardama and Cortes,
2006).
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